Navigation Links
First patent issues on TAL effector technology

EVANSTON, Ill., May 13, 2013 /PRNewswire-iReach/ -- The Two Blades Foundation (2Blades), a not-for-profit organization focused on the development and deployment of durable disease resistance for agriculture, announces the April 16th issuance of a key patent for gene editing based on the use of TAL effectors.

TAL effectors are naturally occurring proteins found in plant pathogenic bacteria that contain a novel repeat structure that binds to specific DNA sequences according to a simple cipher or 'code'.  The discovery of this code enables researchers to target proteins to virtually any DNA sequence in a genome with accuracy and ease to delete, add, alter, or regulate genes with high precision.  The TAL code technology was discovered by Ulla Bonas , Jens Boch , Sebastian Schornack , and Thomas Lahaye at Martin-Luther University in Halle, Germany.  It was named Method of the Year in 2011 by the journal Nature Methods and Best Novel Agricultural Technology in the 2012 Informa Agrow Awards.  2Blades has worked with the inventors to develop the technology and a comprehensive estate of patents.  This issued patent, U.S. Pat. No. 8,420,782, is directed to TAL effectors with endonuclease activity.

2Blades has exclusive rights for commercial uses of the technology in plants. Targeted genome modifications in plants are useful to improve agronomic traits, including disease resistance, growth and yield, or tolerance to environmental conditions such as drought. 2Blades has licensed the technology on a non-exclusive basis to a broad range of leading agricultural companies, including Bayer CropScience, DuPont-Pioneer, KWS SAAT AG, Mendel Biotechnology, Monsanto, Simplot, Syngenta Biotechnology and others. "Interest in licensing the technology for food and fuel applications continues to expand," said 2Blades Chief Operating Officer, Diana Horvath .  In support of 2Blades mission to benefit food security in developing countries, all licenses have a provision to grant back rights to improvements to the technology for 2Blades' efforts for subsistence farming.

The development of TAL effector-based research tools is carried out under an exclusive license to the global biotechnology tools company, Life Technologies Corporation.  Life Technologies has developed a line of products for precision genome engineering known as GeneArt® Precision TALs featuring a number of off the shelf and custom products.  "2Blades and the inventors are truly pleased with our partnership with Life Technologies, "said Horvath. "In a short time, Life has developed a suite of products to make a powerful genome modification platform that is becoming the industry standard." 

About 2Blades

Incorporated in 2004, the Two Blades Foundation (2Blades) is a US based charitable organization that supports programs of research and development on durable disease resistance for practical programs of crop improvement.  The foundation supports the use of safe, environmentally-benign and sustainable strategies for crop production so as to provide long-term protection from crop losses due to disease, with a particular aim of developing disease resistant crops for subsistence agricultures.

Media Contact: Diana Horvath Two Blades Foundation, 847 425 1277,

News distributed by PR Newswire iReach:

SOURCE Two Blades Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
2. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
3. Yongye International Announces First Quarter 2013 Financial Results
4. PDL BioPharma Announces First Quarter 2013 Financial Results
5. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
6. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
7. Vanda Pharmaceuticals Reports First Quarter 2013 Results
8. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
9. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
10. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
11. Yongye International to Report First Quarter 2013 Financial Results on May 10, 2013
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):